Dizal Pharmaceuticals
Clinical trials sponsored by Dizal Pharmaceuticals, explained in plain language.
-
New hope for Tough-to-Treat lung cancers: first patient trial of targeted pill begins
Disease control OngoingThis early-stage study is testing a new oral drug called sunvozertinib (DZD9008) in people with advanced non-small cell lung cancer that has specific mutations in the EGFR or HER2 genes and has worsened after standard treatments. The main goals are to find a safe dose, understand…
Phase: PHASE1, PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug trial aims to outperform chemo for Tough-to-Treat lung cancer
Disease control OngoingThis study is comparing a new targeted drug, DZD9008, against standard platinum-based chemotherapy as the first treatment for adults with advanced non-small cell lung cancer that has a specific genetic mutation (EGFR exon 20 insertion). The main goal is to see if the new drug can…
Phase: PHASE3 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for Tough-to-Treat lymphoma patients
Disease control OngoingThis study is testing an experimental drug called DZD8586 for adults with an aggressive type of lymphoma (DLBCL) that has come back or stopped responding to previous treatments. The main goal is to see if the drug can shrink tumors and control the disease. Researchers will also c…
Phase: PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC